Results 81 to 90 of about 2,001,669 (363)

The multiple roles of the NlpC_P60 peptidase family in mycobacteria – an underexplored target for antimicrobial drug discovery

open access: yesFEBS Letters, EarlyView.
The NlpC_P60 superfamily of peptidases is recognised by its key role in bacterial cell wall homeostasis. Recently, studies have also described the involvement of NlpC_P60‐like enzymes in bacterial competitive mechanisms and pathogenesis across several lineages.
Catharina dos Santos Silva   +1 more
wiley   +1 more source

Pharmacointeraction network models predict unknown drug-drug interactions. [PDF]

open access: yesPLoS ONE, 2013
Drug-drug interactions (DDIs) can lead to serious and potentially lethal adverse events. In recent years, several drugs have been withdrawn from the market due to interaction-related adverse events (AEs).
Aurel Cami   +3 more
doaj   +1 more source

Herbal - Synthetic Drug Interactions

open access: yesMagna Medika, 2023
Background:  Herbal medicine is currently one of the therapeutic options chosen by the community because it is considered relatively safer and has minimal side effects.
Kintoko Kintoko   +7 more
doaj   +1 more source

Predicting potential drugs and drug-drug interactions for drug repositioning [PDF]

open access: yes, 2022
The purpose of drug repositioning is to predict novel treatments for existing drugs. It saves time and reduces cost in drug discovery, especially in preclinical procedures.
Wang, Fei
core  

Making tau amyloid models in vitro: a crucial and underestimated challenge

open access: yesFEBS Letters, EarlyView.
This review highlights the challenges of producing in vitro amyloid assemblies of the tau protein. We review how accurately the existing protocols mimic tau deposits found in the brain of patients affected with tauopathies. We discuss the important properties that should be considered when forming amyloids and the benchmarks that should be used to ...
Julien Broc, Clara Piersson, Yann Fichou
wiley   +1 more source

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

open access: yesMedical Cannabis and Cannabinoids, 2020
Although prescribing information (PI) is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific ...
Paul T. Kocis, Kent E. Vrana
doaj   +1 more source

Systematic discovery of drug interaction mechanisms [PDF]

open access: yes, 2015
Drug combinations are increasingly important in disease treatments, for combating drug resistance, and for elucidating fundamental relationships in cell physiology.
Bollenbach, Mark Tobias   +1 more
core   +2 more sources

The solution supramolecular structure of α2 → 8 polysialic acid suggests a structural cause for its low immunogenicity

open access: yesFEBS Letters, EarlyView.
α2 → 8 polysialic acid elicits poor immunogenicity. Small‐angle scattering shows a supramolecular structure with parallel‐chain binding, although in different forms at μm and mm calcium. The major histocompatibility complex requires molecular weights around 2000 Da to produce antibodies, and 2000 Da polysialic oligomers will bind in these structures ...
Kenneth A. Rubinson
wiley   +1 more source

Provenance for Interactive Visualizations [PDF]

open access: yesarXiv, 2018
We highlight the connections between data provenance and interactive visualizations. To do so, we first incrementally add interactions to a visualization and show how these interactions are readily expressible in terms of provenance. We then describe how an interactive visualization system that natively supports provenance can be easily extended with ...
arxiv  

Refining the NaV1.7 pharmacophore of a class of venom‐derived peptide inhibitors via a combination of in silico screening and rational engineering

open access: yesFEBS Letters, EarlyView.
Venom peptides have shown promise in treating pain. Our study uses computer screening to identify a peptide that targets a sodium channel (NaV1.7) linked to chronic pain. We produced the peptide in the laboratory and refined its design, advancing the search for innovative pain therapies.
Gagan Sharma   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy